Profile data is unavailable for this security.
About the company
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, a selective, covalent inhibitor of ITK (interleukin 2 inducible T cell kinase) and is in a multi-center Phase 1/1b clinical trial in patients with various recurrent, malignant T cell lymphomas. Soquelitinib is designed to inhibit the proliferation of certain malignant T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.
- Revenue in USD (TTM)0.00
- Net income in USD-22.62m
- Incorporated2014
- Employees28.00
- LocationCorvus Pharmaceuticals Inc863 Mitten Rd Ste 102BURLINGAME 94010-1311United StatesUSA
- Phone+1 (650) 900-4520
- Fax+1 (302) 655-5049
- Websitehttps://www.corvuspharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Voyager Therapeutics Inc | 143.77m | 9.02m | 340.83m | 162.00 | 40.74 | 1.02 | 24.54 | 2.37 | 0.1534 | 0.1534 | 2.75 | 6.16 | 0.3825 | -- | 43.56 | 887,462.90 | 2.40 | 0.6378 | 2.71 | 0.8203 | -- | -- | 6.28 | 1.30 | -- | -- | 0.00 | 0.00 | 511.16 | 101.01 | 385.14 | -- | -5.43 | -- |
Cartesian Therapeutics Inc | 54.10m | -229.65m | 342.76m | 38.00 | -- | -- | -- | 6.34 | -38.41 | -38.41 | 5.07 | -5.69 | 0.2221 | -- | 2.89 | 1,423,737.00 | -94.26 | -43.66 | -106.38 | -66.84 | -- | -- | -424.47 | -136.35 | -- | -0.3153 | -- | -- | -76.53 | 95.83 | -721.02 | -- | -25.27 | -- |
Aldeyra Therapeutics Inc | 0.00 | -37.87m | 349.99m | 10.00 | -- | 3.56 | -- | -- | -0.6387 | -0.6387 | 0.00 | 1.65 | 0.00 | -- | -- | 0.00 | -26.89 | -36.79 | -31.76 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1342 | -- | -- | -- | 39.47 | -- | -- | -- |
Lexeo Therapeutics Inc | 0.00 | -77.22m | 356.40m | 58.00 | -- | 2.16 | -- | -- | -2.81 | -2.81 | 0.00 | 4.99 | 0.00 | -- | -- | 0.00 | -60.10 | -- | -68.82 | -- | -- | -- | -- | -- | -- | -- | 0.0097 | -- | -100.00 | -- | -12.01 | -- | -- | -- |
Inozyme Pharma Inc | 0.00 | -88.56m | 359.47m | 59.00 | -- | 3.77 | -- | -- | -1.46 | -1.46 | 0.00 | 1.52 | 0.00 | -- | -- | 0.00 | -57.76 | -45.00 | -63.48 | -48.90 | -- | -- | -- | -- | -- | -- | 0.3244 | -- | -- | -- | -6.13 | -- | 2.85 | -- |
Jasper Therapeutics Inc | 0.00 | -62.44m | 360.71m | 45.00 | -- | 3.60 | -- | -- | -5.10 | -5.10 | 0.00 | 6.64 | 0.00 | -- | -- | 0.00 | -52.45 | -- | -57.00 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.06 | -- | -- | -- |
AC Immune SA | 18.22m | -71.18m | 365.09m | 133.00 | -- | 2.52 | -- | 20.04 | -0.755 | -0.755 | 0.1968 | 1.46 | 0.0787 | -- | 28.76 | 136,985.20 | -30.73 | -18.25 | -42.90 | -19.52 | -- | -- | -390.68 | -148.29 | -- | -128.01 | 0.0255 | -- | 276.14 | 15.52 | 23.35 | -- | -15.49 | -- |
Nkarta Inc | 0.00 | -107.91m | 367.61m | 150.00 | -- | 0.8112 | -- | -- | -2.01 | -2.01 | 0.00 | 6.42 | 0.00 | -- | -- | 0.00 | -21.95 | -32.39 | -23.07 | -34.05 | -- | -- | -- | -372,519.20 | -- | -- | 0.00 | -- | -- | -- | -3.22 | -- | 106.05 | -- |
Alto Neuroscience Inc | -100.00bn | -100.00bn | 369.07m | 78.00 | -- | 2.05 | -- | -- | -- | -- | -- | 6.67 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.053 | -- | -- | -- | -31.02 | -- | -- | -- |
Corvus Pharmaceuticals Inc | 0.00 | -22.62m | 369.68m | 28.00 | -- | 7.22 | -- | -- | -0.4458 | -0.4458 | 0.00 | 0.8189 | 0.00 | -- | -- | 0.00 | -36.89 | -38.31 | -44.60 | -43.34 | -- | -- | -- | -- | -- | -22.18 | 0.00 | -- | -- | -- | 34.57 | -- | -37.45 | -- |
Organogenesis Holdings Inc | 448.39m | -16.54m | 375.19m | 862.00 | -- | 1.42 | -- | 0.8367 | -0.125 | -0.125 | 3.38 | 1.99 | 1.00 | 4.27 | 4.49 | 520,176.30 | -3.70 | 5.46 | -4.51 | 6.90 | 75.14 | 74.94 | -3.69 | 4.81 | 2.42 | 8.33 | 0.2001 | 0.00 | -3.94 | 17.49 | -68.16 | -- | 67.34 | -- |
GH Research PLC | -100.00bn | -100.00bn | 383.97m | 49.00 | -- | 1.93 | -- | -- | -- | -- | -- | 3.82 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0038 | -- | -- | -- | -58.47 | -- | -- | -- |
Nautilus Biotechnology Inc | 0.00 | -69.64m | 386.27m | 164.00 | -- | 1.64 | -- | -- | -0.557 | -0.557 | 0.00 | 1.88 | 0.00 | -- | -- | 0.00 | -23.08 | -- | -23.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.93 | -- | -- | -- |
Lyell Immunopharma Inc | 54.00k | -210.26m | 386.56m | 224.00 | -- | 0.6822 | -- | 7,158.61 | -0.8297 | -0.8297 | 0.0002 | 2.21 | 0.00007 | -- | -- | 241.07 | -28.23 | -- | -29.53 | -- | -- | -- | -389,368.50 | -- | -- | -- | 0.00 | -- | -99.85 | -- | -28.13 | -- | -- | -- |
Monte Rosa Therapeutics Inc | 5.76m | -130.41m | 397.70m | 103.00 | -- | 1.77 | -- | 69.06 | -2.24 | -2.24 | 0.0967 | 3.66 | 0.0185 | -- | 1.05 | 43,300.75 | -41.88 | -- | -46.47 | -- | -- | -- | -2,264.53 | -- | -- | -- | 0.00 | -- | -- | -- | -24.75 | -- | -- | -- |
Northwest Biotherapeutics Inc | 1.65m | -75.55m | 398.06m | 25.00 | -- | -- | -- | 241.98 | -0.0644 | -0.0644 | 0.0014 | -0.047 | 0.0581 | -- | -- | 65,800.00 | -260.06 | -381.58 | -- | -- | -- | -- | -4,479.03 | -6,479.25 | -- | -14.10 | -- | -- | 14.80 | 36.21 | 38.71 | -- | 77.88 | -- |
Holder | Shares | % Held |
---|---|---|
Samlyn Capital LLCas of 01 Aug 2024 | 6.13m | 9.81% |
Point72 Asset Management LPas of 02 May 2024 | 5.96m | 9.54% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 1.48m | 2.36% |
Renaissance Technologies LLCas of 30 Jun 2024 | 563.93k | 0.90% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 516.07k | 0.83% |
Geode Capital Management LLCas of 30 Jun 2024 | 460.14k | 0.74% |
TowerView LLCas of 30 Jun 2024 | 400.00k | 0.64% |
BVF Partners LPas of 31 Mar 2024 | 361.41k | 0.58% |
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 271.84k | 0.44% |
Bridgeway Capital Management LLCas of 31 Mar 2024 | 224.30k | 0.36% |